Article
Detection and monitoring of driver mutations by next-generation sequencing in squamous cell lung cancer patient and possible predictive biomarker of third generation EGFR-tyrosine kinase inhibitors.
Thoracic cancer - 1 Jan 2018
Shen Xiaoyan, Shen Jie, Zhang Hang, Cheng Yuxin, Yang Yang, Gao Jiahui, Zhang Yu, Li Rutian, Liu Baorui, Wang Lifeng
Abstract excerpt
Driver mutation detection and the development of targeted drugs have significantly improved survival of advanced lung adenocarcinoma patients with driver mutations. However, we still lack understanding of druggable mutations in patients with advanced squamous cell lung cancer (SQCLC). Less than 10% of SQCLC patients have EGFR gene mutations, thus we have limited knowledge of biological molecular changes with...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.